Treatment of Refractory Hodgkin's Disease With an Anti-CD16/CD30 Bispecific Antibody
Authors:
Open Access
- 15 March 1997
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 89 (6) , 2042-2047
Abstract
Fifteen patients with refractory Hodgkin's disease were treated in a phase I/II trial with the natural killer (NK)-cell–activating bispecific monoclonal antibody HRS-3/A9, which is directed against the Fcγ-receptor III (CD16 antigen) and the Hodgkin's-associated CD30 antigen, respectively. Median counts of NK cells and of all lymphocyte subsets were considerably decreased in the patients before therapy. HRS-3/A9 was administered 4 times every 3 to 4 days, starting with 1 mg/m2. The treatment was well tolerated, and the maximum tolerated dose was not reached at 64 mg/m2, the highest dose administered because of the limited amounts of HRS-3/A9 available. Side effects were rare and consisted of fever, pain in involved lymph nodes, and a maculopapulous rash. A total of 9 patients developed human antimouse Ig antibodies, and 4 patients developed an allergic reaction after attempted retreatment. A total of 1 complete and 1 partial remission (lasting 16 and 3 months, respectively), 3 minor responses (1 to 11+ months), and 1 mixed response were achieved. There was no clear-cut dose-side effect or dose-response correlation. Our results encourage further clinical trials with this novel immunotherapeutic approach and emphasize the necessity to reduce the immunogenicity of the murine bispecific antibodies.Keywords
This publication has 24 references indexed in Scilit:
- Interleukin-12 increases bispecific-antibody-mediated natural killer cell cytotoxicity against human tumorsCancer Immunology, Immunotherapy, 1996
- CD8 T cell activation after intravenous administration of CD3×CD19 bispecific antibody in patients with non-Hodgkin lymphomaCancer Immunology, Immunotherapy, 1995
- Inhibition of bispecific monoclonal antibody (bsAb)‐targeted cytolysis by human anti‐mouse antibodies in ovarian carcinoma patients treated with bsAb‐targeted activated T‐lymphocytesInternational Journal of Cancer, 1995
- A CD16/CD30 bispecific monoclonal antibody induces lysis of hodgkin's cells by unstimulated natural killer cells In AND In vivoInternational Journal of Cancer, 1993
- Local antitumour treatment in carcinoma patients with bispecific-monoclonal-antibody-redirected T cellsCancer Immunology, Immunotherapy, 1993
- Compartmental analysis of the pharmacokinetics of radioiodinated monoclonal antibody B72.3 in colon cancer patientsNuclear Medicine and Biology, 1993
- Anti‐idiotype vaccine against Hodgkin's lymphoma: Induction of B‐ and T‐cell immunity across species barriers against cd30 antigen by murine monoclonal internal image antibodiesInternational Journal of Cancer, 1992
- Preliminary trial of specific targeting therapy against malignant gliomaThe Lancet, 1990
- Hybrid hybridomas and their use in immunohistochemistryNature, 1983
- The consequences of the chemotherapy of Hodgkin's disease: The 10th David A. Karnofsky memorial lectureCancer, 1981